Skip to main content

Table 4 Hazard ratios (CCLG vs. GPOH) according to local treatment modality

From: Survival is influenced by approaches to local treatment of Ewing sarcoma within an international randomised controlled trial: analysis of EICESS-92

  Local treatment modality Subdivision of RT and surgery group
None
N = 23
Radiotherapy (RT) alone
N = 164
Surgery alone
N = 138
RT and surgery
N = 289
RT then surgery
N = 201
Surgery then RT
N = 88
No. events
 EFS 21 105 53 131 93 38
 OS 19 92 41 109 79 30
Unadjusted
 EFS 20 (2.64–161) 0.86 (0.58–1.26) 1.31 (0.76–2.25) 1.67 (1.05–2.66) 2.22 (0.81–6.07) 1.99 (1.05–3.78)
 OS 1.50 (0.56–3.96) 0.95 (0.63–1.44) 1.50 (0.81–2.80) 1.65 (1.00–2.74) 1.96 (0.72–5.37) 2.10 (1.02–4.30)
Adjusted for age, metastatic disease, primary site and histology
 EFS 53 (4.0–477) 0.92 (0.62–1.38) 1.24 (0.70–2.20) 1.82 (1.12–2.94) 2.40 (0.84–6.84) 2.50 (1.24–5.06)
 OS 2.09 (0.64–6.79) 1.06 (0.69–1.63) 1.41 (0.73–2.74) 1.81 (1.07–3.05) 2.21 (0.77–6.35) 2.76 (1.26–6.05)
Adjusted for age, metastatic disease, primary site, histology and time between the start of chemotherapy and starting local treatment
 EFS   0.91 (0.60–1.38) 1.24 (0.70–2.19) 1.61 (0.96–2.70) 1.98 (0.70–5.60) 2.83 (1.30–6.16)
 OS   1.04 (0.67–1.63) 1.43 (0.73–2.78) 1.68 (0.97–2.91) 1.94 (0.68–5.58) 3.39 (1.42–8.06)
  1. Hazard ratios greater than 1 indicate that CCLG patients had a higher risk of having an event or dying compared to GPOH patients
  2. Based on data excluding patients with unknown primary site because there were so few
  3. EFS event-free survival; OS overall survival